Q32 Bio Inc. (QTTB) Cash & Equivalents (2017 - 2026)

Q32 Bio has reported Cash & Equivalents for 10 years, with the latest figure at $106.3 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 93.86% year-over-year to $106.3 million in Q2 2026; TTM through Jun 2026 was $106.3 million, a 93.86% increase from a year earlier, with the FY2025 full-year figure at $48.3 million, down 38.05% from the prior year.
• Cash & Equivalents was $106.3 million for Q2 2026 at Q32 Bio, up from $50.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $248.1 million in Q1 2022, with the low at $20.1 million in Q2 2023.
• Average Cash & Equivalents over 5 years is $76.1 million, with a median of $52.8 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 88.62% in 2023, then soared 386.94% in 2024.
• Over 5 years, Cash & Equivalents stood at $34.0 million in 2022, then dropped by 24.62% to $25.6 million in 2023, then soared by 204.35% to $78.0 million in 2024, then sank by 38.05% to $48.3 million in 2025, then soared by 120.1% to $106.3 million in 2026.
• The last three Cash & Equivalents figures came in at $106.3 million (Q2 2026), $50.8 million (Q1 2026), and $48.3 million (Q4 2025), per Business Quant data.